Navigation Links
Dynogen Reports Positive Results in Phase 1B GERD Study

," said Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. "DDP733, which targets the GI motility abnormalities central to GERD, has demonstrated a statistically significant reduction in the number of reflux events at a dose of 0.5 mg in this trial. We are now planning a larger Phase 2 study in GERD patients, where we will further build on these very promising results."

In February of this year, Dynogen announced positive results from its Phase 2 study of DDP733 in IBS-c, with a statistically significant improvement over placebo in the Subject Global Assessment of IBS. The Company plans to initiate a Phase 2b study in IBS-c this year.

About DDP733

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT(3)). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. Preclinical studies of DDP733 established the compound's prokinetic properties (the ability to promote the motility of the GI tract). Dynogen's preclinical studies have also shown that DDP733 is minimally absorbed by the cells lining the gastrointestinal tract and, as a result, more of the product candidate remains available at the desired local site of action. A recently completed Phase 2 study of the candidate as a treatment for IBS-c demonstrated an overall clinical response rate of 54% in patients receiving a dose of 1.4 mg t.i.d. compared to a 15% clinical response rate for patients receiving placebo, and the drug was also well-tolerated. Previous clinical studies of the compound have demonstrated favorable safety and pharmacokinetic profiles. Dynogen has exclusive rights under issued U.S. and European patents related to the use of DDP733 as a treatment for GERD.

About Nocturnal Gastroesophageal Reflux Disease (NGERD)

Gastroesophageal reflux disease (GERD) is a chronic condition that afflicts approximately 20 percent of adults in the United States. Persistent heartburn
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dynogens DDP733 Reduces Reflux in Phase 1b GERD Study
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen Reports Positive Results Phase GERD Study
(Date:7/7/2015)... NEW YORK , July 7, 2015 /PRNewswire/ ... Welch Allyn for $2 billion in cash and ... competitive patient monitoring market, according to Kalorama Information. ... heretofore participated in the medical device and advanced ... maker of hospital beds, patient lifting devices, and ...
(Date:7/7/2015)... 7, 2015 According to ... Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, ... Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, ... by MarketsandMarkets, this report studies the global Nuclear ... to 2020. This market is expected to reach ...
(Date:7/7/2015)... July 7, 2015 A power morcellator lawsuit ... been settled for an undisclosed amount, Bernstein Liebhard LLP ... in March 2014 in the U.S. District Court, Eastern ... of a widower whose wife had died in February ... hysterectomy that involved the use of a power morcellator. ...
Breaking Medicine Technology:Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 2Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 4Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3
... 2011 Today, Osseon® Therapeutics, Inc. launched the ... in Osseon,s suite of minimally invasive products for ... (Photo:   http://photos.prnewswire.com/prnh/20110901/SF61461 ) The Osseoflex ... vertebral body. The Osseoplasty™ procedure offers unparalleled flexibility ...
... N.Y., Sept. 1, 2011 Polar ( www.polarusa.com ), ... technologies, today introduced the Polar Move . The ... needs of the education market. Its introduction solidifies Polar ... building on the success of schools who have used ...
Cached Medicine Technology:Osseon® Announces Commercial Release of Osseoflex®SN (Steerable Needle) 2New Polar Move Heart Rate Monitor for Students Facilitates Effective and Safe Physical Education 2New Polar Move Heart Rate Monitor for Students Facilitates Effective and Safe Physical Education 3New Polar Move Heart Rate Monitor for Students Facilitates Effective and Safe Physical Education 4
(Date:7/7/2015)... ... July 07, 2015 , ... Leading healthcare consulting firm Hammes ... Senior Vice President, heading the firm’s Healthcare Advisory Services division. , Mr. Warden ... healthcare providers’ needs in ways that strengthen their position in the marketplace. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more than ... original 2015 fundraising goal by nearly $100,000, to help support children fighting ...
(Date:7/7/2015)... ... ... Difass USA, a modern supplement brand committed to excellence, understands that sometimes ... knowing that there is hopefully a vacation to look forward to this summer. But ... a vacation can be quite stressful, and it’s difficult sometimes to fully disconnect and ...
(Date:7/7/2015)... ... 07, 2015 , ... This week Northeast Nebraska Imaging, Norfolk’s ... The website’s goal is to provide patients with detailed information about the various ... appointments online. , Part of the center’s rebranding efforts, the website was designed ...
(Date:7/7/2015)... Seattle, Washington (PRWEB) , ... ... ... and San Francisco-based Hope Consulting announced today that the two firms have ... organizations in the social, health and biopharma sectors. The merger combines SwitchPoint’s ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2
... Brooks Kushman,P.C., a leading intellectual property and technology law ... behalf of the National,Multiple Sclerosis (MS) Society, Michigan Chapter, ... team raised nearly $7,000,which will help support MS research ... The team, "BK Stomps on MS," participated in ...
... care makes a difference , , ... critical areas, Joint Commission-accredited hospitals in America have steadily improved ... lives and improving the health of thousands of patients, according ... Commission,s Report on Quality and Safety 2008 , an ...
... antidepressant fluoxetine during the first three months of pregnancy gave ... as women who did not and the levels were three ... the conditions were serious, others were not severe and resolved ... three-country study in the November issue of the British ...
... ADT Capability in DoseTrac(TM) Improves Communication and Safety, Promotes Ease ... Pa., Nov. 24 In an industry first that will ... as they streamline care, B. Braun Medical Inc. (B. Braun) ... with Inbound Admission, Discharge and Transfer (ADT) Interface capabilities . ...
... RSNA Booth # 6221 -- Varian,Medical Systems, Inc. (NYSE: ... and flat-panel,digital detectors for filmless X-ray imaging in a ... (RSNA) meeting in Chicago from November,30 -- December 3, ... technologies, and introduce a powerful new oncology picture,archiving and ...
... CENTENNIAL, Colo., Nov. 24 LABS Inc., one of ... has added,Dr. Carol Pancoska, a leading figure in the ... Laboratory Directors. , ... field of immunology for,over thirty years. She has held ...
Cached Medicine News:Health News:Brooks Kushman Stomps on Multiple Sclerosis: Local Law Firm Honored by Multiple Sclerosis Society for Fundraising Efforts 2Health News:Joint Commission Report Shows Gains in Safety, Quality 2Health News:Joint Commission Report Shows Gains in Safety, Quality 3Health News:Joint Commission Report Shows Gains in Safety, Quality 4Health News:Pregnancy study finds strong association between two antidepressants and heart anomalies 2Health News:Pregnancy study finds strong association between two antidepressants and heart anomalies 3Health News:B. Braun's DoseTrac(TM) Software: Making Connections to Better Manage IV Therapy 2Health News:B. Braun's DoseTrac(TM) Software: Making Connections to Better Manage IV Therapy 3Health News:B. Braun's DoseTrac(TM) Software: Making Connections to Better Manage IV Therapy 4Health News:Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, X-Ray Tubes, and Cancer Treatment Technologies at RSNA This Year 2Health News:Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, X-Ray Tubes, and Cancer Treatment Technologies at RSNA This Year 3Health News:LABS Inc. Adds Dr. Carol Pancoska as Laboratory Director 2
Rapid Tumor Marker Test: Prostate Specific Antigen...
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
... Sensitivity is Recognized as a Valuable ... Caused by Early Eye Disease. Near ... x 7 in (12.7cm x 17.78cm) ... a Refractor,Distance Test F.A.C.T. 201: ...
Medicine Products: